Pfizer Inc. (NYSE:PFE) Shares Acquired by HHM Wealth Advisors LLC

HHM Wealth Advisors LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 51.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 9,347 shares of the biopharmaceutical company’s stock after buying an additional 3,184 shares during the quarter. HHM Wealth Advisors LLC’s holdings in Pfizer were worth $248,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer in the fourth quarter worth about $26,000. Gladius Capital Management LP boosted its stake in Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares during the period. Quarry LP purchased a new position in Pfizer during the 2nd quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in Pfizer during the 3rd quarter valued at $35,000. Finally, Joseph Group Capital Management lifted its holdings in shares of Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 771 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 1.1 %

NYSE PFE opened at $26.23 on Tuesday. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market cap of $148.62 billion, a PE ratio of 35.44, a PEG ratio of 0.66 and a beta of 0.64. The firm has a 50-day simple moving average of $26.27 and a 200 day simple moving average of $27.85.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.56%. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is presently 232.44%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PFE. Citigroup dropped their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. UBS Group lowered their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Bank of America restated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.